Immunai

We are proud to expand our partnership with AstraZeneca in a multi-year collaboration aimed at optimizing clinical trials in oncology. By leveraging our AI-powered platforms, we’re working together to enhance clinical decision-making and accelerate drug development in oncology. Building on our shared success since 2022, this collaboration focuses on tackling some of the biggest challenges in clinical trials, like dose selection and patient responses, to bring new therapies to patients faster and more efficiently. Learn more about our new multi-year partnership here: https://lnkd.in/dFKTDczZ

Drug development is changing, and AI is at the center of it. That’s why we’re excited to welcome?Mikael Dolsten?to our Board of Directors. With decades of leadership in R&D, immunology, and precision medicine—including his role in bringing 35+ therapies to market—Mikael’s expertise will help us shape the next era of AI-driven drug discovery at Immunai.? His guidance will strengthen how we analyze immune responses, identify promising drug candidates, and accelerate the path from discovery to treatment. Please join us in welcoming Mikael to the Immunai family!? https://lnkd.in/dGnCQ8Kb #AI #Biotech #DrugDiscovery #Immunai

On World Cancer Day, we stand with patients, caregivers, physicians, researchers, and developers in the fight against cancer. At Immunai, we are harnessing the power of AI and single-cell genomics to unlock the full potential of the immune system—advancing precision oncology and revolutionizing how cancer is treated. Together, we can transform the future of cancer treatment. #WorldCancerDay #Immunai #AIforCancer

?? Kicking off 2025 with another edition of our “Inside Immunai” series! We’re thrilled to spotlight Eva Macuchova, our Scientific Team Lead, whose work has been pivotal in advancing Immunai’s mission. Eva’s journey began in 2017 as a biocurator at Nebion, a Swiss company specializing in transcriptomic data integration. Over the years, she honed her skills in data cleaning, integration, and annotation, transforming raw datasets into valuable resources for research. When Nebion was acquired by Immunai in 2021, Eva embraced the opportunity to grow alongside a company at the forefront of single-cell immunology and AI-powered discovery. Now, leading a team of talented metadata curators, Eva ensures scientific data is standardized, harmonized, and accessible. Her work fuels our AMICA platform that accelerates discoveries in cancer and inflammatory research. When she’s not curating data, Eva enjoys reading crime stories and exploring new restaurants as a self-proclaimed foodie! Her fascination with solving mysteries aligns perfectly with her role at Immunai! ?? Thank you, Eva, for your dedication and expertise in helping shape the future of immunology and personalized medicine. Join our team and work with Eva! https://lnkd.in/dri8bPpS #Biotech #AI #Immunology #Innovation #Healthcare

We’ve been named Startup of the Week by The Innovator!? Mapping the immune system is a task that many thought was impossible. At Immunai, we believe that with the right technology and approach, even the most complex systems can be understood and transformed.? Today, our AMICA platform is the world’s largest single-cell immune knowledge base, with data on 80+ cell types, 500 diseases, and insights from 10,000+ patient samples. Our CEO, Noam Solomon, speaks with Jennifer Schenker about how we can pave the way for preventive medicine by regularly measuring immune health https://lnkd.in/dMDvcaeJ #biotech #immune system #AI?

Humbled to attend the Davos World Economic Forum annual meeting, and meet with world leaders and top entrepreneurs. Looking forward to an inspiring week!

This week, our CEO, Noam Solomon is in Davos, representing Immunai as part of the World Economic Forum’s Unicorn Program, recognizing the high-growth companies shaping the future of their industries. It's an incredible honor to have Immunai join global leaders, visionaries, and changemakers shaping the future of AI, biotech, and beyond. Attending the forum? Let’s connect! https://lnkd.in/dYxiXFUF

Despite its potential, AI hasn’t solved the biggest challenges in therapeutics. The issue? Outdated preclinical data, poor biological insights, and a lack of connection between preclinical and clinical outcomes. We’re taking a different approach. By mapping the immune system and harmonizing datasets, we’re bridging the gap between discovery and clinical success. This approach is important to unlocking AI’s potential and delivering better, faster treatments for patients. Read?Adeeb Rahman, Ansuman Satpathy,?and?Noam Solomon’s latest op-ed with?HIT Consultant Media:?https://lnkd.in/dYpWAzPY

Building the future of cancer treatment starts with a simple value: team above all. At Immunai, collaboration is at the core of everything we do. Healthy debate, shared commitment, and valuing collective success over individual recognition have helped us build partnerships with AstraZeneca and Teva Pharmaceuticals to advance cancer research. Thank you to Micha Y. Breakstone ??????? and Inc. Magazine for highlighting how our values shape our work and impact. Read more: https://lnkd.in/d9uGikED

Developing new drugs is a complex and lengthy process, with 95% of treatments failing before they reach patients. Our CEO, Noam Solomon, recently joined Maayan Hoffman on ILTV News’s Lights of Hope panel to discuss how our immune cell atlas is tackling key challenges like optimizing drug dosages and identifying effective treatment combinations.? Alongside Karin Noy from Pfizer, the panel shared how AI is improving clinical trial efficiency and boosting success rates. Watch the full interview here: https://lnkd.in/d7gaPuES